Eli Lilly Announces Pivotal Phase 3 Success for Orforglipron as Once Daily Oral Treatment for Type 2 Diabetes
The global landscape for metabolic medicine shifted significantly in October 2025 as pharmaceutical leader Eli Lilly and Company announced that…
